ArticleLife (Basel, Switzerland)2026
Limitations of MMSE in Cognitive Assessment: Revealing Latent Risk via Structural Brain Atrophy.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oxidative stress biomarkers and flavonoids in Alzheimer's disease: current clinical evidence and therapeutic perspectives.Redox report : communications in free radical research · 2026Review
- Regional Brain Volume Variation Across Adulthood: A Cross-Sectional MRI Analysis of Age, Sex, and Hemispheric Asymmetry.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The primary objective of this study was to evaluate the relative contributions of the MMSE and nWBV in three-class cognitive stage classification, with a secondary objective of conducting a subgroup analysis to investigate latent risk within the MMSE-normal population. To achieve this, we proposed an explainable deep-learning-based analytical framework integrating the MMSE with nWBV, a structural brain atrophy indicator, and systematically assessed the relative contributions of each variable in cognitive impairment stage classification and potential risk screening. Although the MMSE is widely used in clinical practice as a cognitive screening tool, it has limited sensitivity to early or subtle cognitive decline and may not adequately reflect structural brain changes due to the ceiling effect. To address this limitation, we compared four tabular deep learning models-MLP, Tab ResNet, Tab Transformer, and FT Transformer-under identical fivefold cross-validation conditions. Age and sex were fixed as covariates, and feature ablation analysis was conducted to examine the independent and combined effects of the MMSE and nWBV. The results showed no statistically significant differences in classification performance among model architectures, indicating that predictive performance was primarily determined by the informational content of the input variables rather than model complexity. In the feature ablation analysis, the MMSE alone demonstrated strong discriminative power, whereas nWBV alone showed relatively limited performance; however, when combined with the MMSE, nWBV consistently improved classification performance. Furthermore, for interpretability analysis, both Integrated Gradients (IG) and SHAP were applied to validate variable contributions from complementary perspectives. Across both methods, the MMSE and nWBV were repeatedly identified as key contributing features, and interpretability stability was maintained throughout cross-validation folds, supporting the robustness and reliability of the explanatory results. Beyond simple model performance comparisons, this study provides evidence supporting the complementary integration of structural brain atrophy information into MMSE-centered traditional cognitive assessment by jointly considering variable contribution and interpretability stability. This approach is expected to contribute to precision risk screening and clinical decision support in the early stages of cognitive decline. Although the MMSE exhibited strong discriminative performance, nWBV provided complementary structural risk signals within the MMSE-normal subgroup, suggesting that integrating cognitive assessment with structural biomarkers may enhance early risk identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.